123 Main Street, New York, NY 10001

Top Navigation with Mega Menu

Co-Dx™ Logix Smart® ZDC (ZIKV-DENV-CHIKV) test kit

Boost speed and accuracy with real-time PCR testing

The Co-Dx Logix Smart ZDC test kit uses our patented Co-Primers™ technology to differentiate between the RNA of Zika, dengue (all 4 serotypes), and chikungunya viruses and to detect and amplify regions of the viruses’ genomes.

Man in a lab testing for Zika, dengue, and chikungunya viruses

How it works

The test operates using a single step real-time reverse transcriptase polymerase chain reaction (RT-PCR) process in serum samples, collected alongside with urine, from patients suspected of being infected with Zika, dengue, or chikungunya.

The Co-Dx Logix Smart ZDC test kit is designed and validated to identify Zika, dengue, or chikungunya viruses even when more than one target is present, such as in co-infections. The presence of one target does not interfere with detection of any other targets. If a patient specimen is positive for Zika, a CSF specimen can also be collected to search for neurological infection.

Test kit components

The Co-Dx Logix Smart ZDC test kit includes the following components.

Ready-to-use Master Mix

Includes the complete mix for convenience and an Internal Positive Control (IPC) - Human RNaseP gene marker

Positive Control

Synthetic control intended to amplify all targets included in the kit to ensure integrity of the entire run

Negative Control

Acts as a negative control to verify Master Mix is free from contamination

Additional information​

The Co-Dx Logix Smart ZDC test kit is intended for molecular biology applications to aid in the differentiation and diagnosis of Zika, dengue, and chikungunya in human serum and urine specimens. It is recommended for serum to be collected alongside a urine sample.

The Co-Dx Logix Smart ZDC test kit was designed and validated as a real-time RT-PCR kit that targets and differentiates between conserved regions in the genomes of the three pathogens.

This assay can be broken down into 3 stages: sample preparation, reverse transcription, and the polymerase chain reaction with real-time monitoring. The assay has an IPC that also acts as an extraction control to monitor the extraction, amplification, and detection steps.

Test kit performance & specifications

Application

Qualitative PCR screening

Sample type
Serum or plasma, with urine
Type of detection
Presence/absence of Zika, dengue, and chikungunya viruses
Thermocycler Run Time

50 cycles (60-90 minutes, depending on PCR equipment)

Thermocycler
Most 4-channel machines, including Co-Dx Box™
Zika Virus
Serum
Plasma
Urine
CSF
Dengue Virus
Serum
Plasma
Chikungunya
Serum
Plasma
Sensitivity
97.2% (92-99.4%)
93.2% (90.2-95.6%)
91%
(77-98%)
96%
(80-100%)
98%
(89-100%)
99.33% (98.68-99.71%)
99%
(94-100%)
94.4% (91.9-96.3%)
Specificity
100% (99.3-100%)
100% (99.82-100%)
100%
(90-100%)
100%
(81-100%)
100% (93.3-100%)
100% (99.82-100%)
100% (93.3-100%)
100% (99.82-100%)

Limit of detection data 

Marker
Specimen
Strain
Estimated LoD
Zika Virus
Serum
Asian lineage, PRVABC59
African lineage, MR766
3.19×104 copies/mL
3.23×104 copies/mL
Plasma
Asian lineage, PRVABC59
1.52 x104 copies/mL
Urine
Asian lineage, PRVABC59
6.23×104 copies/mL
CSF
Asian lineage, PRVABC59
4.83×104 copies/mL
Chikungunya
Virus
Serum
S27 Persfield
1.03×103 copies/mL
Plasma
R91064
4.27×103 copies/mL
Dengue Virus Types 1-4
Plasma
Type 1 (Quantitative synthetic RNA template)
Synthetic RNA template
Dengue Type 2, New Guinea C
Dengue Type 3, H87
Dengue Type 3, H341
2.11×105 copies/mL
8.21×104 copies/mL
9.08×104 copies/mL
5.05×104 copies/mL
2.69×105 copies/mL
Plasma
Dengue Type 1, Hawaii
Dengue Type 2, New Guinea C
Dengue Type 3, H87
Dengue Type 3, H341
4.03×102 PFU/mL
7.27×10 PFU/mL
1.91×102 PFU/mL
6.13×102 PFU/mL

* Results obtained from observational study of 2364 datapoints obtained from the contrived samples

Request a quote​

Contact us for more information about the Co-Dx Logix Smart ZDC test kit.

Get started

Every test from Co-Dx is designed to be easy to use.

About the diseases​

Zika Virus

Zika virus (ZIKV) is a Flaviviridae family virus. It is spread by daytime-active Aedes mosquitoes, such as A. aegypti and A. albopictus. The virus was first isolated in 1947 in monkeys and is named after the Zika Forest in Uganda. In 1952, the first human cases of Zika were detected and since then, outbreaks of Zika have been reported in Africa, the Americas, Asia, and the Pacific.

Given Zika’s ability to be passed along via sexual transmission in addition to mosquito vectors, the key component to preventing the spread of the disease is an early, accurate, and affordable diagnosis for both men and women.

Dengue Virus

Like Zika, dengue (DENV) is a mosquito borne-viral infection spread by the daytime-active Aedes mosquito species A. aegypti and A. albopictus. Dengue fever is a flu-like illness. There are 4 genotypes/serotypes of dengue virus (DENV1, DENV2, DENV3, and DENV4). Immunity is acquired for long periods for each type, although the immunity to one type does not prevent the infection from the other types. In hyperendemic areas, infection of dengue virus is as frequent as up to four times per individual. The illness spectrum varies from asymptomatic, classic dengue fever, and severe or hemorrhagic dengue fever, which can be fatal (Wilder-Smith & Gubler, 2008). Halstead & O’Rourke (1977) proposed that the severe dengue condition could be caused by an antibody dependent enhancement (ADE) response where the antibodies acquired in a previous infection enhances the immune response to following infectious causing dengue shock syndrome, which can be fatal.

Chikungunya Virus

Like Zika and dengue, chikungunya (CHIKV) is a mosquito borne-viral infection transmitted by the bite of the daytime-active Aedes mosquito species A. aegypti and A. albopictus. The symptoms of chikungunya include fever and joint pain very similar to Zika and dengue. The disease can be severe, especially for young children and the elderly. Patients can develop a post-acute or chronic arthropathy lasting 21 to 90 days in acute cases, and three months to more than two years in chronic cases (PAHO/WHO, 2017).

Regulatory clearance

In March 2019, the Co-Dx Logix Smart ZDC test kit received CE mark approval, the principle regulatory clearance allowing the test to be sold as an in vitro diagnostic (IVD) for the diagnosis of Zika, dengue, and/or chikungunya in European Union states and other markets that accept a CE-IVD marking as valid regulatory approval.

This product is for export only and is not for sale in the United States.